化学抵抗性细胞群体的表征改善了儿科AML的风险分层和治疗预测
Mohammad Javad NajafPanah1, Alexandra M Stevens1, Michael J Krueger1
1Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
bioRxiv : the preprint server for biology
|November 19, 2025
概括
新的研究确定了在诊断时儿科急性髓性白血病 (pAML) 中的耐化学性细胞. 检测这些细胞可以改善风险预测,帮助高风险患者进行向治疗,降低死亡率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 儿科急性髓性白血病 (pAML) 尽管接受化疗,但复发率很高.
- 目前的预后工具缺乏准确性来识别高风险患者.
- 像干细胞移植 (SCT) 这样的激进治疗方法具有显著的毒性.
研究的目的:
- 为pAML.开发一个更准确的早期风险预测模型.
- 为了识别pAML中的化学抵抗的新生物标志物.
- 发现高风险pAML的潜在治疗点.
主要方法:
- 从33名pAML患者的对诊断复发样本的单细胞分辨率分析.
- 开发一种风险预测模型,其中包括耐化细胞种群.
- 鉴定出耐化学反应细胞的分子特征.
主要成果:
- 诊断时的耐化学性细胞种群显著改善了pAML风险预测.
- 确定了一个以前未被认可的高风险亚组 (20%的病例) 与<40%的无事件生存率.
- 这一小组在第一次缓解时没有接受SCT的患者中占死亡的50%.
结论:
- 早期检测耐化学药细胞可以完善pAML风险分层.
- 鉴定耐化细胞揭示了高风险pAML的潜在治疗点.
- 改进的风险预测可以指导个性化治疗策略,并改善儿科急性髓性白血病患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K


